Senti Biosciences (NASDAQ:SNTI - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at Chardan Capital in a research note issued on Friday,Benzinga reports. They presently have a $12.00 price target on the stock. Chardan Capital's target price would suggest a potential upside of 261.45% from the company's current price.
Senti Biosciences Price Performance
SNTI stock traded up $0.07 during trading on Friday, hitting $3.32. 42,230 shares of the company traded hands, compared to its average volume of 804,429. Senti Biosciences has a 1 year low of $1.52 and a 1 year high of $16.94. The company has a market cap of $86.33 million, a PE ratio of -0.21 and a beta of 2.32. The stock's 50-day simple moving average is $3.48 and its 200 day simple moving average is $3.66.
Senti Biosciences (NASDAQ:SNTI - Get Free Report) last posted its earnings results on Thursday, March 20th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($3.13) by $2.46. The business had revenue of $5.86 million for the quarter, compared to analyst estimates of $2.80 million. Research analysts expect that Senti Biosciences will post -14.54 earnings per share for the current year.
Institutional Investors Weigh In On Senti Biosciences
A hedge fund recently bought a new stake in Senti Biosciences stock. Renaissance Technologies LLC bought a new stake in Senti Biosciences, Inc. (NASDAQ:SNTI - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 51,600 shares of the company's stock, valued at approximately $181,000. Renaissance Technologies LLC owned 1.07% of Senti Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 25.73% of the company's stock.
About Senti Biosciences
(
Get Free Report)
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Read More
Before you consider Senti Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.
While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
